|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/dc06-1628
© 2007 by the American Diabetes Association
Emerging Treatments and Technologies |
Transfer to Sulphonylurea Therapy in Adult Subjects With Permanent Neonatal Diabetes Due to KCNJ11-Activating Mutations
Evidence for improvement in insulin sensitivity
1 Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland
2 Department of Pediatrics, Institute of Pediatrics, Medical University of Lodz, Lodz, Poland
Address correspondence and reprint requests to Maciej T. Malecki, MD, PhD, Department of Metabolic Diseases, Jagiellonian University, Medical College, 15 Kopernika St., 31-501 Krakow, Poland. E-mail: mmalecki@cm-uj.krakow.pl
Abbreviations: KATP channel, ATP-sensitive K+ channel • PND, permanent neonatal diabetes
| The first 20% of the full text of this article appears below. |
 |
INTRODUCTION |
|---|
Activating mutations in the KCJN11 gene encoding in the ATP-sensitive K+ channel (KATP channel) subunit Kir6.2 were reported (1) as the most common cause of permanent neonatal diabetes (PND). Recently, it has been shown that most subjects with Kir6.2 mutations could be switched from insulin to sulfonylurea and that such treatment is both safe and highly effective, at least in the short term (2,3). Notably, the majority of reported successfully transferred patients were children. Data on adults are very scarce, and there are few mutation carriers transferred off insulin (2,4). Moreover, some adult subjects are unable to switch from insulin to sulfonylurea (2).
We have recently identified four adult carriers of a Kir6.2 mutation and provided evidence that they, before the sulfonylurea exposure, were characterized by decreased insulin sensitivity (5). Here, we report their successful transfer to sulfonylurea.
|
RESEARCH DESIGN AND METHODS— |
|---|
To dissect the genetic background of PND in Poland, the Nationwide Registry has recently been established. Four adult subjects with Kir6.2-activating mutations were identified by the end of 2005. Three subjects carried the R210H mutation, while one individual had the K170N substitution. They were included in the current project, which aimed to switch from insulin to sulfonylurea and to assess, by hyperinsulinemic-euglycemic clamp, whether the alteration in insulin action occurs after this transfer. The study protocol and informed-consent procedures were approved by the ethics committee of Jagiellonian
|
RESULTS— |
|---|
|
CONCLUSIONS— |
|---|
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Aguilar-Bryan and J. Bryan Neonatal Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 265 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rafiq, S. E. Flanagan, A.-M. Patch, B. M. Shields, S. Ellard, A. T. Hattersley, and The Neonatal Diabetes International Collaborative Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations Diabetes Care, February 1, 2008; 31(2): 204 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Gurgel, F. Crispim, M. H. S. Noffs, E. Belzunces, M. A. Rahal, and R. S. Moises Sulfonylrea Treatment in Permanent Neonatal Diabetes Due to G53D Mutation in the KCNJ11 Gene: Improvement in glycemic control and neurological function Diabetes Care, November 1, 2007; 30(11): e108 - e108. [Full Text] [PDF]
|
|
|
|
|
|
A. Gach, K. Wyka, M. T. Malecki, A. Noczynska, J. Skupien, J. Nazim, M. Szalecki, J. Bodalski, J. Sieradzki, and W. Mlynarski Islet-Specific Antibody Seroconversion in Patients With Long Duration of Permanent Neonatal Diabetes Caused by Mutations in the KCNJ11 Gene Diabetes Care, August 1, 2007; 30(8): 2080 - 2082. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |